Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.21M | $15.2M | $22.5M | $24.9M | $41.0M | $43.2M | $34.7M | $31.1M | $35.6M | $37.1M |
| Revenue growth | — | 84.6% | 48.5% | 10.9% | 64.4% | 5.3% | -19.6% | -10.4% | 14.5% | 4.1% |
| Gross profit | $5.57M | $9.63M | $15.0M | $17.6M | $30.0M | $32.1M | $20.7M | $22.0M | $24.9M | $26.5M |
| Gross margin | 67.9% | 63.6% | 66.7% | 70.5% | 73.0% | 74.4% | 59.8% | 70.6% | 69.9% | 71.5% |
| Operating income | -$11.5M | -$9.84M | -$15.6M | -$19.0M | -$10.4M | -$22.7M | -$31.5M | -$31.9M | -$16.5M | -$14.7M |
| Operating margin | -140.0% | -65.0% | -69.3% | -76.0% | -25.3% | -52.7% | -90.9% | -102.8% | -46.2% | -39.8% |
| Net income | -$11.8M | -$8.46M | -$17.2M | -$19.3M | -$7.84M | -$24.6M | -$32.8M | -$29.2M | -$20.7M | -$8.20M |
| Net margin | -143.4% | -55.8% | -76.5% | -77.2% | -19.1% | -56.9% | -94.6% | -94.1% | -58.2% | -22.1% |
| EPS (diluted) | -$0.46 | -$0.32 | -$0.56 | -$0.60 | -$0.20 | -$0.57 | -$0.75 | -$0.65 | -$0.38 | -$0.13 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.73M | -$6.46M | -$10.8M | -$16.8M | -$5.61M | -$14.0M | -$28.2M | -$21.7M | -$14.4M | -$12.4M |
| Capital expenditures | $141K | $991K | $672K | $698K | $708K | $3.64M | $6.09M | $538K | $284K | $164K |
| Free cash flow | -$6.87M | -$7.45M | -$11.5M | -$17.5M | -$6.32M | -$17.6M | -$34.3M | -$22.2M | -$14.7M | -$12.5M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $5.25M | $17.3M | $22.4M | $12.2M | $71.4M | $52.1M | $22.1M | $14.1M | $3.28M | $6.25M |
| Total assets | $9.69M | $24.1M | $34.2M | $27.4M | $90.0M | $89.5M | $63.2M | $57.5M | $47.4M | $44.2M |
| Total liabilities | $8.36M | $13.8M | $17.3M | $24.0M | $10.7M | $26.9M | $27.9M | $27.5M | $36.3M | $38.3M |
| Long-term debt | $4.08M | $5.99M | $9.27M | $13.4M | $0.00 | — | $5.00M | $2.54M | $14.0M | $16.7M |
| Shareholders' equity | $1.34M | $10.3M | $16.9M | $3.42M | $79.2M | $62.6M | $35.4M | $23.5M | $11.1M | $5.90M |
| Retained earnings | -$144M | -$152M | -$170M | -$189M | -$197M | -$221M | -$254M | -$261M | -$304M | -$312M |
| Shares (wtd avg diluted) | 25.5M | 29.0M | 31.8M | 32.3M | 38.8M | 43.4M | 43.6M | 44.7M | 54.4M | 62.2M |
Every figure is extracted from Cytosorbents Corp’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.